Budesonide (Uceris rectal foam) vs hydrocortisone (Cortenema)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: Glucocorticoid receptor · full Ulcerative Colitis pipeline
Budesonide (Uceris rectal foam)
Marketed by Bausch Health
NCT01008423 · Phase 3 · completed
The study was a randomized, triple-blind, placebo-controlled trial with 134 participants receiving budesonide and 147 receiving placebo. Its primary endpoint was a clinical-and-endoscopic remission measure, and the comparison significantly favored budesonide at week 6 (44.0% vs 22.4%, p<0.0001).
No aligned efficacy figure on record for this race.
hydrocortisone (Cortenema)
Marketed by ANI Pharmaceuticals, Inc.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Budesonide (Uceris rectal foam) | hydrocortisone (Cortenema) |
|---|---|---|
| Clinical remission (induction) | —Not reported | —Not reported |
| Clinical remission (maintenance) | —Not reported | —Not reported |
| Clinical response (induction) | —Not reported | —Not reported |
| Endoscopic improvement (induction) | —Not reported | —Not reported |
| Corticosteroid-free remission (maintenance) | —Not reported | —Not reported |
Clinical remission (induction)
- Budesonide (Uceris rectal foam)
- —Not reported
- hydrocortisone (Cortenema)
- —Not reported
Clinical remission (maintenance)
- Budesonide (Uceris rectal foam)
- —Not reported
- hydrocortisone (Cortenema)
- —Not reported
Clinical response (induction)
- Budesonide (Uceris rectal foam)
- —Not reported
- hydrocortisone (Cortenema)
- —Not reported
Endoscopic improvement (induction)
- Budesonide (Uceris rectal foam)
- —Not reported
- hydrocortisone (Cortenema)
- —Not reported
Corticosteroid-free remission (maintenance)
- Budesonide (Uceris rectal foam)
- —Not reported
- hydrocortisone (Cortenema)
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Budesonide (Uceris rectal foam): registry results are on file for Ulcerative Colitis, but their comparison mappings are not yet available.
hydrocortisone (Cortenema): no structured comparison results are available for Ulcerative Colitis.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Budesonide (Uceris rectal foam)'s landscape · hydrocortisone (Cortenema)'s landscape